Theravance Biopharma, Inc. Payments for Restructuring
Theravance Biopharma, Inc. (TBPH) reported Payments for Restructuring of $1.19 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2024-03-01
- Theravance Biopharma, Inc. payments for restructuring for the quarter ending 2023-12-31 was $0.00.
- Theravance Biopharma, Inc. payments for restructuring for the quarter ending 2023-09-30 was $14.00K, a 96.42% decline year-over-year.
- Theravance Biopharma, Inc. payments for restructuring for the quarter ending 2023-06-30 was $575.00K, a 85.47% decline year-over-year.
- Theravance Biopharma, Inc. payments for restructuring for the quarter ending 2023-03-31 was $599.00K, a 94.69% decline year-over-year.
- Theravance Biopharma, Inc. payments for restructuring for fiscal 2023 was $1.19M, a 92.40% decline from fiscal 2022.
- Theravance Biopharma, Inc. payments for restructuring for fiscal 2022 was $15.62M, a 574.32% increase from fiscal 2021.
- Theravance Biopharma, Inc. payments for restructuring for fiscal 2021 was $2.32M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $14.00K derived: sum of 2 quarters · filed 2024-03-01 | $589.00K derived: sum of 3 quarters · filed 2024-03-01 | $1.19M 10-K · filed 2024-03-01 |
| 2023-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $589.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.19M 10-Q · filed 2023-11-09 | $1.19M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $575.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.17M 10-Q · filed 2023-08-09 | $1.17M derived: sum of 3 quarters · filed 2023-08-09 | $1.56M derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | $599.00K 10-Q · filed 2023-05-10 | $599.00K derived: sum of 2 quarters · filed 2023-05-10 | $990.00K derived: sum of 3 quarters · filed 2023-05-10 | $4.95M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $391.00K derived: sum of 2 quarters · filed 2023-03-01 | $4.35M derived: sum of 3 quarters · filed 2023-03-01 | $15.62M 10-K · filed 2023-03-01 |
| 2022-09-30 | $391.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.35M derived: sum of 2 quarters · filed 2022-11-09 | $15.62M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $15.23M 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $11.28M 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | $2.32M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |